Merck, Pfizer end patent feud over pneumococcal vaccines with royalty-centered settlement
A long-running patent battle between two pharma giants over their competing pneumococcal conjugate vaccines has come to an end.
Merck and Pfizer have reached a settlement agreement to dismiss patent claims for all their PCV products, Merck announced Thursday. It’s a deal that comes just a few months after both companies netted approvals for new vaccines, with Pfizer getting the rubber stamp for its 20-valent shot in June and Merck winning the green light for a 15-valent vaccine in July.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.